SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

Rong Xu; Difei Lian; Yan Xie; Zhilei Chen; Yan Wang; Lin Mu; Yuan Wang; Baoyu Zhang

doi:10.31083/j.fbl2807134

SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

Front Biosci (Landmark Ed). 2023 Jul 6;28(7):134. doi: 10.31083/j.fbl2807134.

Authors

Rong Xu^{1

2}, Difei Lian^{1

2}, Yan Xie^{1

2}, Zhilei Chen^{1

2}, Yan Wang^{1

2}, Lin Mu^{1

2}, Yuan Wang^{1

2}, Baoyu Zhang^{1

2}

Affiliations

¹ Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China.
² Beijing Key Laboratory of Diabetes Research and Care, 100000 Beijing, China.

PMID: 37525911
DOI: 10.31083/j.fbl2807134

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.

Keywords: SGLT-2 inhibitors; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; type 2 diabetes.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / metabolism
Humans
Liver / metabolism
Non-alcoholic Fatty Liver Disease* / metabolism
Obesity / metabolism
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors